Li T - Search Results

1

STING agonist inflames the cervical cancer immune microenvironment and overcomes anti-PD-1 therapy resistance.

Li T, Zhang W, Niu M, Wu Y, Deng X, Zhou J. Li T, et al. Front Immunol. 2024 Mar 14;15:1342647. doi: 10.3389/fimmu.2024.1342647. eCollection 2024. Front Immunol. 2024. PMID: 38550593 Free PMC article.

2

Epidemiological trends of women's cancers from 1990 to 2019 at the global, regional, and national levels: a population-based study.

Yi M, Li T, Niu M, Luo S, Chu Q, Wu K. Yi M, et al. Among authors: li t. Biomark Res. 2021 Jul 7;9(1):55. doi: 10.1186/s40364-021-00310-y. Biomark Res. 2021. PMID: 34233747 Free PMC article.

3

TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy.

Yi M, Li T, Niu M, Wu Y, Zhao Z, Wu K. Yi M, et al. Among authors: li t. Front Immunol. 2022 Dec 19;13:1061394. doi: 10.3389/fimmu.2022.1061394. eCollection 2022. Front Immunol. 2022. PMID: 36601124 Free PMC article. Review.

4

EREG is a risk factor for the prognosis of patients with cervical cancer.

Li T, Feng R, Chen B, Zhou J. Li T, et al. Front Med (Lausanne). 2023 Mar 20;10:1161835. doi: 10.3389/fmed.2023.1161835. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37020674 Free PMC article.

5

Targeting PARP for the optimal immunotherapy efficiency in gynecologic malignancies.

Li T, Wang X, Qin S, Chen B, Yi M, Zhou J. Li T, et al. Biomed Pharmacother. 2023 Jun;162:114712. doi: 10.1016/j.biopha.2023.114712. Epub 2023 Apr 17. Biomed Pharmacother. 2023. PMID: 37075667 Free article. Review.

6

Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy.

Li T, Wang X, Niu M, Wang M, Zhou J, Wu K, Yi M. Li T, et al. Front Immunol. 2023 Jul 13;14:1196970. doi: 10.3389/fimmu.2023.1196970. eCollection 2023. Front Immunol. 2023. PMID: 37520520 Free PMC article. Review.

7

Vascular normalization: reshaping the tumor microenvironment and augmenting antitumor immunity for ovarian cancer.

Yu P, Wang Y, Yuan D, Sun Y, Qin S, Li T. Yu P, et al. Among authors: li t. Front Immunol. 2023 Oct 23;14:1276694. doi: 10.3389/fimmu.2023.1276694. eCollection 2023. Front Immunol. 2023. PMID: 37936692 Free PMC article. Review.

8

Exploiting innate immunity for cancer immunotherapy.

Yi M, Li T, Niu M, Mei Q, Zhao B, Chu Q, Dai Z, Wu K. Yi M, et al. Among authors: li t. Mol Cancer. 2023 Nov 27;22(1):187. doi: 10.1186/s12943-023-01885-w. Mol Cancer. 2023. PMID: 38008741 Free PMC article. Review.

9

S100A8/A9 as a risk factor for breast cancer negatively regulated by DACH1.

Zhang X, Niu M, Li T, Wu Y, Gao J, Yi M, Wu K. Zhang X, et al. Among authors: li t. Biomark Res. 2023 Dec 13;11(1):106. doi: 10.1186/s40364-023-00548-8. Biomark Res. 2023. PMID: 38093319 Free PMC article.

10

CAR-NK cells for cancer immunotherapy: recent advances and future directions.

Li T, Niu M, Zhang W, Qin S, Zhou J, Yi M. Li T, et al. Front Immunol. 2024 Feb 9;15:1361194. doi: 10.3389/fimmu.2024.1361194. eCollection 2024. Front Immunol. 2024. PMID: 38404574 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

39,379 results

Search Page

Filters